JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Cytek Biosciences Inc

Chiusa

SettoreSettore sanitario

4.42 -3.49

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.35

Massimo

4.55

Metriche Chiave

By Trading Economics

Entrata

-39M

-44M

Vendite

9.8M

62M

Margine di Profitto

-70.929

Dipendenti

702

EBITDA

4M

-263K

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+40.13% upside

Dividendi

By Dow Jones

Utili prossimi

7 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

12M

573M

Apertura precedente

7.91

Chiusura precedente

4.42

Notizie sul Sentiment di mercato

By Acuity

50%

50%

177 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Cytek Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 apr 2026, 23:33 UTC

Azioni calde

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 apr 2026, 23:24 UTC

Utili

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 apr 2026, 23:15 UTC

Principali Notizie su Eventi

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 apr 2026, 22:46 UTC

Utili

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 apr 2026, 22:37 UTC

Utili

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 apr 2026, 22:15 UTC

Utili
Principali Notizie su Eventi

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 apr 2026, 23:33 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 apr 2026, 23:31 UTC

Utili

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 apr 2026, 23:31 UTC

Utili

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 apr 2026, 23:30 UTC

Utili

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 apr 2026, 23:30 UTC

Utili

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 apr 2026, 23:19 UTC

Discorsi di Mercato
Utili

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 apr 2026, 23:09 UTC

Utili

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 apr 2026, 23:03 UTC

Discorsi di Mercato

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 apr 2026, 22:51 UTC

Utili

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 apr 2026, 22:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

28 apr 2026, 22:48 UTC

Discorsi di Mercato

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 apr 2026, 22:40 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 apr 2026, 22:32 UTC

Utili

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 apr 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 apr 2026, 22:22 UTC

Utili

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 apr 2026, 22:17 UTC

Discorsi di Mercato

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 apr 2026, 22:14 UTC

Utili

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 apr 2026, 22:14 UTC

Utili

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 apr 2026, 22:07 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Confronto tra pari

Modifica del prezzo

Cytek Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

40.13% in crescita

Previsioni per 12 mesi

Media 6.25 USD  40.13%

Alto 7.5 USD

Basso 5 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytek Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

1

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

3.7 / 3.8Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

177 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat